Phaseline

Companies › Bial R&D Investments

Bial R&D Investments: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BIA 28-6156
Glucocerebrosidase activator
GBAPhase 2Parkinson's Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05819359BIA 28-6156Phase 2Parkinson's DiseaseNeurologyApr 2026

Targets

GBA (1)

Companies with the same targets

Lingyi Biotech Spur Therapeutics Prevail Therapeutics Azafaros

Companies built like this

Aptinyx Neuron23 SHINKEI Therapeutics NeuroTherapia Clene Nanomedicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.